dc.contributor.author | Heinrich, MC | |
dc.contributor.author | Jones, RL | |
dc.contributor.author | von Mehren, M | |
dc.contributor.author | Schoffski, P | |
dc.contributor.author | Serrano, C | |
dc.contributor.author | Kang, Y-K | |
dc.contributor.author | Cassier, PA | |
dc.contributor.author | Mir, O | |
dc.contributor.author | Eskens, F | |
dc.contributor.author | Tap, WD | |
dc.contributor.author | Rutkowski, P | |
dc.contributor.author | Chawla, SP | |
dc.contributor.author | Trent, J | |
dc.contributor.author | Tugnait, M | |
dc.contributor.author | Evans, EK | |
dc.contributor.author | Lauz, T | |
dc.contributor.author | Zhou, T | |
dc.contributor.author | Roche, M | |
dc.contributor.author | Wolf, BB | |
dc.contributor.author | Bauer, S | |
dc.contributor.author | George, S | |
dc.date.accessioned | 2022-09-15T13:06:23Z | |
dc.date.available | 2022-09-15T13:06:23Z | |
dc.date.issued | 2020-09-01 | |
dc.identifier.citation | The Lancet Oncology, 2020, 21 (9), pp. E418 - E418 | en_US |
dc.identifier.issn | 1470-2045 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/5485 | |
dc.identifier.eissn | 1474-5488 | |
dc.identifier.eissn | 1474-5488 | |
dc.format.extent | E418 - E418 | |
dc.language | English | |
dc.language.iso | eng | en_US |
dc.publisher | ELSEVIER SCIENCE INC | en_US |
dc.relation.ispartof | The Lancet Oncology | |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/4.0/ | en_US |
dc.subject | Science & Technology | |
dc.subject | Life Sciences & Biomedicine | |
dc.subject | Oncology | |
dc.title | Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial (vol 21, pg 935, 2020) | en_US |
dc.type | Journal Article | |
dcterms.dateAccepted | 2021-06-09 | |
dc.date.updated | 2022-09-15T13:05:33Z | |
rioxxterms.version | VoR | en_US |
rioxxterms.licenseref.startdate | 2020-09-01 | |
rioxxterms.type | Journal Article/Review | en_US |
pubs.author-url | https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000568490900044&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=d4b848928d1c3e5c86d298abb68475f9 | |
pubs.issue | 9 | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Sarcoma Clinical Trials (R Jones) | |
pubs.organisational-group | /ICR/Primary Group/Royal Marsden Clinical Units | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Sarcoma Clinical Trials (R Jones)/Sarcoma Clinical Trials (R Jones) (hon.) | |
pubs.publication-status | Published | |
pubs.volume | 21 | |
dc.contributor.icrauthor | Jones, Robin | |
icr.provenance | Deposited by Mr Arek Surman on 2022-09-15. Deposit type is initial. No. of files: 1. Files: jco.21.00217.pdf | |